Vasoflux

Drug Profile

Vasoflux

Latest Information Update: 08 Jun 2000

Price : $50

At a glance

  • Originator GLYCODesign
  • Class
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke; Thrombosis

Most Recent Events

  • 08 Jun 2000 A study has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials sections
  • 14 Sep 1999 Discontinued-II for Thrombosis in North America (IV)
  • 14 Sep 1999 Discontinued-Clinical for Stroke in North America (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top